CONMED Corporation

NYSE:CNMD

Medical - Devices

Healthcare
$48.01 +0.75%

+$0.24 today

Market cap
$1.43B
Beta
0.92
P/E (TTM)
18.0
EPS (TTM)
$1.79
Dividend yield
1.24%
52W Low $31.84High $56.64

Volume 0.36M

Average 0.45M

CNMD Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

CONMED CorporationNYSE: CNMD

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $141.7M fell 1.2% year over year, behind the +4.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.

Context

  • Selling, general & admin amounted to 38.4% of revenue in FY2025, up 1.8 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $544.8M (+3.1%) for the fiscal year ending Dec 2026, a slowdown from the +10.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$141.7M+7.7% QoQ
Last fiscal yearDec 2025
$528.36M+10.5% YoY
LTMMar 2026
$522.58M+4.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.2%+8.3%+9.5 pp
1 year+10.5%+3.1%-7.4 pp
3-year CAGR+5.2%+4.4%-0.8 pp
5-year CAGR+4.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
528.36M USD
Year-over-year change
+10.5%
4-year CAGR
+6.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CNMD compares with its peers on the latest reported figures

  • CNMD's LTM Mar 2026 selling, general & admin of $522.58M is the highest of the 11 companies compared; the peer median is $181.5M.
  • Its year-over-year change of +4.9% is the 5th highest of 11, against a peer median of +2.4%.
  • Selling, general & admin amounts to 38.1% of revenue for CNMD, versus a peer median of 51.5%.
CNMD Competitors Peer median
Selling, General & Admin for CNMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNMDCONMED CorporationLTM Mar 2026$522.58M +4.9%+5.2%38.1%
NVCRNovoCure LimitedLTM Mar 2026$461.38M +6.1%+10.9%68.4%
NEOGNeogen CorporationLTM Aug 2026$406.6M -0.9%+6.3%46.0%
AHCOAdaptHealth Corp.LTM Apr 2026$385.95M -14.8%+33.1%13.5%
AZTAAzenta, Inc.LTM Sep 2026$256.31M +1.6%-2.9%41.2%
INMDInMode Ltd.LTM Mar 2026$197.82M +3.3%+4.1%52.8%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$165.19M +100.5%—197.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$157.94M +14.5%+9.9%239.0%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$135.66M -17.8%+9.4%51.4%
UFPTUFP Technologies, Inc.LTM Jun 2026$83.81M +16.7%+19.1%13.3%
SSIISS Innovations International, Inc.LTM Mar 2026$25.03M +1.3%+55.7%51.7%
Peer median (excluding CNMD) $181.5M+2.4%+9.9%51.5%

Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.01B1.05B1.24B1.31B1.37B
Cost of Revenue442.6M474.23M568.5M573.98M649.12M
Gross Profit568.04M571.25M676.25M733.03M725.38M
Gross Margin56.2%54.6%54.3%56.1%52.8%
Research & Development43.57M47.15M52.6M54.43M55.88M
Selling, General & Admin414.75M454.04M503.04M478.28M528.36M
Operating Expenses458.32M501.19M555.64M532.71M584.24M
Depreciation & Amortization70.74M49.76M71.87M71.86M52.34M
EBITDA179.33M7.8M192.48M272.18M154.55M
EBITDA Margin17.7%0.7%15.5%20.8%11.2%
Operating Income109.72M70.05M120.6M200.33M141.13M
Operating Margin10.9%6.7%9.7%15.3%10.3%
Interest Income00000
Interest Expense35.49M28.91M39.78M37.3M31.09M
Other Income / Expenses(36.61M)(140.92M)(39.78M)(37.3M)(70.01M)
Income Before Tax73.11M(70.86M)80.83M163.03M71.12M
Pre-Tax Margin7.2%-6.8%6.5%12.5%5.2%
Income Tax Expense10.56M9.72M16.37M30.61M24.06M
Net Income62.54M(80.58M)64.46M132.42M47.06M
Net Margin6.2%-7.7%5.2%10.1%3.4%
EPS (Basic)2.14(2.68)2.104.291.52
EPS (Diluted)1.94(2.68)2.044.261.51
Weighted Avg Shares29.16M30.04M30.67M30.85M31.04M
Weighted Avg Shares (Diluted)32.22M30.04M31.55M31.11M31.15M

CONMED Corporation

NYSE:CNMD

Intrinsic Alpha fair value

Locked

Current Price

$48.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.